Carib A. Oquendo

Array ( [id] => 12702412 [patent_doc_number] => 20180125970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => METHODS FOR TREATING LUNG CANCER [patent_app_type] => utility [patent_app_number] => 15/566888 [patent_app_country] => US [patent_app_date] => 2016-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15566888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107640 [patent_doc_number] => 20160304611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'COMBINATION THERAPY FOR TREATING ADULT PATIENTS WITH RELAPSED/REFRACTORY CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA' [patent_app_type] => utility [patent_app_number] => 15/098961 [patent_app_country] => US [patent_app_date] => 2016-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 18777 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15098961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13510491 [patent_doc_number] => 20180306788 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING HYDROXYLATION OF ACC2 BY PHD3 [patent_app_type] => utility [patent_app_number] => 15/564956 [patent_app_country] => US [patent_app_date] => 2016-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -94 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15564956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11046251 [patent_doc_number] => 20160243209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'TUMOR ANTIGEN BASED ON PRODUCTS OF THE TUMOR SUPPRESSOR GENE WT1' [patent_app_type] => utility [patent_app_number] => 15/091111 [patent_app_country] => US [patent_app_date] => 2016-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 4924 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15091111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11032952 [patent_doc_number] => 20160229909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-11 [patent_title] => 'Monoclonal Antibodies That Inhibit The Wnt Signaling Pathway and Methods of Production and Use Thereof' [patent_app_type] => utility [patent_app_number] => 15/089937 [patent_app_country] => US [patent_app_date] => 2016-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 30840 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15089937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15245271 [patent_doc_number] => 10508149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-17 [patent_title] => Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) [patent_app_type] => utility [patent_app_number] => 15/563924 [patent_app_country] => US [patent_app_date] => 2016-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 9 [patent_no_of_words] => 15997 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15563924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12408630 [patent_doc_number] => 09969809 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-15 [patent_title] => Therapeutic antibodies and their uses [patent_app_type] => utility [patent_app_number] => 15/085644 [patent_app_country] => US [patent_app_date] => 2016-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 39 [patent_no_of_words] => 54887 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15085644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11075738 [patent_doc_number] => 20160272702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'ANTI-CCL8 THERAPY FOR BREAST CANCER' [patent_app_type] => utility [patent_app_number] => 15/072643 [patent_app_country] => US [patent_app_date] => 2016-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7354 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15072643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12660526 [patent_doc_number] => 20180112008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => ANTI-MUC16 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/558694 [patent_app_country] => US [patent_app_date] => 2016-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -179 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15558694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14519155 [patent_doc_number] => 10336824 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-02 [patent_title] => Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof [patent_app_type] => utility [patent_app_number] => 15/069622 [patent_app_country] => US [patent_app_date] => 2016-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 53 [patent_no_of_words] => 83450 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15069622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11421374 [patent_doc_number] => 20170029518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'ANTI-BCMA ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/065641 [patent_app_country] => US [patent_app_date] => 2016-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 16034 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15065641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11834701 [patent_doc_number] => 20170216421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'MANUFACTURING OF MULTI-DOSE INJECTION READY DENDRITIC CELL VACCINES, COMBINATION THERAPIES FOR BLOCKING HER2 AND HER3, AND ESTROGEN RECEPTOR POSITIVE HER2 BREAST RECEPTOR POSITIVE HER2 BREAST CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 15/327023 [patent_app_country] => US [patent_app_date] => 2016-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 30589 [patent_no_of_claims] => 65 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15327023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11060799 [patent_doc_number] => 20160257761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'HER2/neu-Specific Antibodies and Methods of Using Same' [patent_app_type] => utility [patent_app_number] => 15/061452 [patent_app_country] => US [patent_app_date] => 2016-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 33451 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15061452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12908986 [patent_doc_number] => 20180194837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/551710 [patent_app_country] => US [patent_app_date] => 2016-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15551710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11060789 [patent_doc_number] => 20160257751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'ANTIBODY THERAPEUTICS THAT BIND CD47' [patent_app_type] => utility [patent_app_number] => 15/061771 [patent_app_country] => US [patent_app_date] => 2016-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 31952 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15061771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185744 [patent_doc_number] => 20180044681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'METHODS OF TREATING CANCER HARBORING HEMIZYGOUS LOSS OF TP53' [patent_app_type] => utility [patent_app_number] => 15/555411 [patent_app_country] => US [patent_app_date] => 2016-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 16121 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15555411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12448482 [patent_doc_number] => 09982013 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Readily isolated bispecific antibodies with native immunoglobulin format [patent_app_type] => utility [patent_app_number] => 15/058026 [patent_app_country] => US [patent_app_date] => 2016-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 13 [patent_no_of_words] => 15693 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15058026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10997442 [patent_doc_number] => 20160194388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-07 [patent_title] => 'MONOCLONAL ANTIBODIES TO HUMAN 14-3-3 EPSILON AND HUMAN 14-3-3 EPSILON SV' [patent_app_type] => utility [patent_app_number] => 15/054691 [patent_app_country] => US [patent_app_date] => 2016-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 25758 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15054691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12158878 [patent_doc_number] => 20180030144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'CD73 BLOCKADE' [patent_app_type] => utility [patent_app_number] => 15/551919 [patent_app_country] => US [patent_app_date] => 2016-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 35489 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15551919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16799106 [patent_doc_number] => 10994022 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-04 [patent_title] => Detection and treatment of malignant tumours in the CNS [patent_app_type] => utility [patent_app_number] => 15/550837 [patent_app_country] => US [patent_app_date] => 2016-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 28572 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15550837 [rel_patent_id] =>[rel_patent_doc_number] =>)